Leaflet: information for the user
Calmiox 5 mg/g topical foam
Hydrocortisone
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
This medicine can be obtained without a prescription. However, for the best results, it should be used properly.
1. What is Calmiox and what it is used for
2. What you need to know before starting to use Calmiox
3. How to use Calmiox
4. Possible side effects
5. Storage of Calmiox
6. Contents of the pack and additional information
It is a topical medication that contains hydrocortisone, a corticosteroid that relieves skin itching.
It is indicated for the temporary local symptomatic relief of skin itching (but not pain) due to small skin irritations, contact allergy with soaps, detergents, metals, insect bites, and nettle stings.
Do not use Calmiox
Do not apply this medication to the eyes or mucous membranes, including anal, genital, or oral mucous membranes, as it is only for external use on the skin.
Warnings and precautions
Consult your doctor if you experience blurred vision or other visual disturbances.
Consult your doctor or pharmacist before starting to use Calmiox.
Be especially careful with Calmiox
Use of Calmiox with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Although no interactions have been described between Calmiox and other medications, it should not be used simultaneously with other preparations in the same area, unless prescribed by a doctor.
Interference with diagnostic tests
Calmiox may interfere with adrenal function diagnostic tests that may decrease, as well as blood and urine glucose concentrations that may be increased if the medication has been absorbed.
Pregnancy and lactation
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
No effects have been described that affect driving or operating machinery.
Important information about some of the components of Calmiox
This medication may cause local skin reactions (such as contact dermatitis) or eye and mucous membrane irritation because it contains butylhydroxytoluene (E321).
It may cause allergic reactions (possibly delayed) because it contains methylparaben (E218) and propylparaben (E216).
Follow exactly the medication administration instructions contained in this leaflet or those indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist.
Calmiox is for topical use.Shake before use and keep in an upright position during use.
-Adults and adolescents 12 years of age and older:Applya thin film to the affected area.The usual dose is 1 or 2 applications per day.
-Children under 12 years of age: consult a doctor.
-Use in patients 65 years of age and older: consult a doctor.
Wash your hands thoroughly after use.
Do not apply for more than 7 consecutive days without consulting a doctor, in any case.
If you use more Calmiox than you should
Due to prolonged use or on large skin areas, the manifestation of adverse reactions increases.
In caseof overdose or accidental ingestion, go immediately to a medical center or call the Toxicological Information Service, phone 91 562.04.20, indicating the medication and the amount ingested.
If you forgot to use Calmiox
Do not use a double dose to compensate for the missed doses.
Like all medications, this medication may produce adverse effects, although not all people will experience them. Adverse effects are rare at the administered doses, generally occurring in prolonged use beyond 7 days and in extensive areas or with occlusive dressings, disappearing upon discontinuation of treatment or reduction in administration frequency.
The following adverse effects may occur:
Rare Adverse Effects(may affect up to 1 in 1,000 patients)
Very Rare Adverse Effects(may affect up to 1 in 10,000 patients)
Adverse Effects of Unknown Frequency(cannot be estimated from available data):
In childrenwith chronic treatments, isolated cases ofincreased intracranial pressure and adrenal suppression have been described, manifesting as delayed growth and increased weight; chronic therapy may interfere with child development.
Reporting Adverse Effects:
If you experience any type of adverse effect, consult your doctor even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Attention. Contains 6% by mass of flammable components. Pressurized container: May burst if heated. Keep away from heat, hot surfaces, sparks, open flames, and any other ignition source. Do not smoke. Do not pierce or burn, even after use. Protect from sunlight. Do not expose to temperatures above 122°F/50°C.
Store below 30°C
Do not use Calmiox after the expiration date appearing on the container after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash.Deposit the containers and the
medicines you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. In this way, you will help protect the environment.
Calmiox Composition
The active principle is hydrocortisone.
Calmiox contains 5 mg of hydrocortisone per gram (5 mg/g).
The other components are stearic acid, cetearil octanoate, octyldodecanol, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), butylhydroxytoluene (E321), disodium edetate, sorbitan estearate, polisorbate 60, carboxymethyl cellulose, sodium hydroxide, bronopol, purified water, and propano/isobutane.
Product appearance and packaging contents
Calmiox is presented in aluminum monobloc aerosol containers with epoxy-coated interiors, equipped with valves and diffusers. Each container contains 50 g of foam.
Marketing Authorization Holder
Esteve Pharmaceuticals, S.A.
Passeig de la Zona Franca, 109- 08038 Barcelona
Spain
Responsible for manufacturing
RECIPHARM PARETS, S.L.
Ramón y Cajal, 2- 08150 Parets del Valles
Barcelona - Spain
Last review date of this leaflet:09/2017
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.